01024nam0 2200253 i 450 VAN006413620160906114829.5820080423d1979 |0itac50 bagerDE|||| |||||Griechische Plastik von den Anfangen bis zum Ausgang des HellenismusAufnahmen von Max HirmerMünchenHirmerc1979159 p., [141] c. di tav.ill.30 cm.MünchenVANL001057LulliesReinhardVANV039734183981HirmerMaxVANV036842HirmerVANV109725650ITSOL20230616RICABIBLIOTECA DEL DIPARTIMENTO DI LETTERE E BENI CULTURALIIT-CE0103VAN07VAN0064136BIBLIOTECA DEL DIPARTIMENTO DI LETTERE E BENI CULTURALI07CONS Oa 1314 07 7124 20080423 Griechische Plastik von den Anfangen bis zum Ausgang des Hellenismus1416127UNICAMPANIA04545nam 2201021z- 450 991058593580332120220812(CKB)5600000000483127(oapen)https://directory.doabooks.org/handle/20.500.12854/91177(oapen)doab91177(EXLCZ)99560000000048312720202208d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierRisk Prediction and New Prophylaxis Strategies for Thromboembolism in CancerBaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (202 p.)3-0365-4707-X 3-0365-4708-8 Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed.Medicine and NursingbicsscOncologybicsscALKanticoagulantsarterial thrombosiscancercancer associated thrombosiscancer-associated venous thromboembolismchemotherapycoagulation activationcoumarinsdeep vein thrombosisdirect oral anticoagulantdirect oral anticoagulantsDOACDOACsendogenous heparinheparan sulfateheparanaseHodgkin lymphomahospiceintegrated careKRASlocally advanced breast cancerlow molecular weight heparinlow molecular weight heparinslow-molecular weight heparinlow-molecular-weight heparin (LMWH)lymphomamalignancymolecular subtypemultiple myeloman/aneoplasmsNon-Hodgkin lymphomapalliative care unitspancreatic cancerpCRprognostic modelprophylaxispulmonary embolismrisk assessment modelsrisk factorsROS1simultaneous caresurvivalthromboprophylaxisthrombosistreatmentUFHvenous thromboembolismVKAVTEMedicine and NursingOncologyFerroni Patriziaedt1280411Roselli MarioedtGuadagni FiorellaedtFerroni PatriziaothRoselli MarioothGuadagni FiorellaothBOOK9910585935803321Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer3016900UNINA